Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic di...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisondi, Paolo, Geat, Davide, Maurelli, Martina, Degli Esposti, Luca, Bellinato, Francesco, Girolomoni, Giampiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142895/
https://www.ncbi.nlm.nih.gov/pubmed/35632402
http://dx.doi.org/10.3390/vaccines10050646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142895/
https://www.ncbi.nlm.nih.gov/pubmed/35632402
http://dx.doi.org/10.3390/vaccines10050646

Ejemplares similares